chmp present neg opinion even
chmp adopt neg opinion even base cv risk amgen/ucb
expect appeal committe medicin product human use
chmp european medicin agenc ema adopt neg
opinion market author applic amgen/ucb
even treatment sever osteoporosi base cardiovascular risk
cv compani expect submit appeal follow regulatori
challeng us ucb previous discuss possibl
investor today news complet unexpect partner
view eu least valuabl region term even estim
eu opportun worth per share
even could still gain approv appeal recal even
experienc challeng gain fda approv ultim black box
warn cv concern phase trial eventu
gain fda approv resubmit bla member vote ye
less like today opinion could still gain ema approv
appeal
european sale even expect modest contribut
valuat even per term partnership
state develop cost futur world-wide commerci
profit loss share equal approv ema expect ex-u
end-us sale even contribut oper
incom cost profit share grow
even signific driver growth share
out-performance await outcom appeal ema approv
process adjust outlook overal even core
compon outperform thesi expect upsid
biosimilar novel oncolog drive signific growth even
absenc eu even sale
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biotechnolog compani engag
discoveri develop manufactur market human
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario assum tvgr better
current assumpt base-busi greater
current forecast assum greater expect
growth biosimilar franchis slower expect
declin base busi also assum posit data
readout pipelin asset regulatori
approv abp kanjinti us abp abp
lower base busi sale poorer growth profil
biosimilar busi key pipelin asset assum
slower expect growth biosimilar franchis
regulatori headwind drug approv ip litig
scenario assum lose patent litig soliri
enbrel also assum neg data readout pipelin asset
 close
compani mention price
